TruAlt Bioenergy Releases Transcript of Q3 FY26 Earnings Call
TruAlt Bioenergy released its Q3 FY26 earnings call transcript. The company achieved over 95% capacity utilization in its ethanol plants, with a monthly revenue run rate of ₹350-400 crores. CBG business reported EBITDA margins of 63% and PAT margins of 43%. Plans include 24 new CBG units and a 100 million liters/annum SAF plant with ₹2,000 crore capex. Q3 FY26 revenue grew 70% to ₹730.86 crores.
The announcement provides detailed financial results, strategic business updates across multiple segments (ethanol, CBG, SAF, retail), and future expansion plans with significant capex. This information is material for investors.
The company reported strong revenue growth, high capacity utilization in its ethanol plants, and positive performance in its CBG segment. Future expansion plans in SAF and CBG, along with government support, indicate a positive outlook.
TruAlt Bioenergy Limited has released the transcript of its earnings conference call held on February 9, 2026, to discuss the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The transcript is also available on the company's website.
During the call, the management highlighted the strategic importance of biofuels for India's energy security. In the ethanol sector, the company reported that its four operational ethanol plants achieved over 95% capacity utilization on operating days, with Unit 5 receiving its consent to operate on December 17, 2025. All five ethanol plants are now fully operational, supporting a monthly revenue run rate of approximately ₹350-400 crores, with a gross production of around 5.5-6 crore liters per month. The company has completed its planned capital expenditure for grain-based integration and does not plan further expansion in the ethanol business.
In the Compressed Biogas (CBG) business, the company achieved an EBITDA margin of 63% and a PAT margin of 43% for the nine months ended December 31, 2025. TruAlt Bioenergy plans to develop 24 Greenfield CBG units over the next two to three years through joint ventures with Sumitomo Corporation and GAIL. Four new plants are under construction and scheduled for commissioning by July 2026 with Sumitomo. GAIL's equity infusion for their joint venture is expected within February 2026, enabling the commissioning of 10 CBG plants.
For the Sustainable Aviation Fuel (SAF) segment, the company has progressed with a technology licensing agreement with Honeywell UOP for a proposed 100 million liters per annum SAF facility in Andhra Pradesh. The company is also seeking INR150 crores of Viability Gap Funding under the PM JI-VAN scheme and is in advanced discussions with Sumitomo Corporation for potential equity participation. The projected capex for the SAF plant is upwards of ₹2,000 crores, with a target completion by July-October 2027.
The retail business has seen the commissioning of seven biofuel retail outlets within six months, with plans to scale to approximately 75 outlets in FY2026. Financially, for the nine months ended December 31, 2025, the company reported a total income of ₹1,187 crores, a 13.28% increase from the previous year. The consolidated profit after tax (PAT) stood at ₹35.92 crores. For the quarter ended December 31, 2025, the total income grew by 70% to ₹730.86 crores, with PAT at ₹69.19 crores.
The company expects stronger revenue momentum and margin expansion in Q4 FY26 due to improved utilizations and absorption of fixed costs. The CBG segment contributed ₹30.97 crores in revenue for the nine months ended December 31, 2025, with EBITDA and PAT margins of 63.34% and 43.38% respectively. The company also reported DDGS revenue of ₹18 crores for Q3 FY26, with an expectation of ₹70-80 crores in Q4 FY26. The management is confident in meeting ethanol supply obligations despite past shortfalls, supported by a High Court directive.
What to do with a filing like this
TruAlt Bioenergy Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by TruAlt Bioenergy Limited. Read the original for the full detail.